Table 2.
Patients’ characteristics grouped by colonisation status (non-community B vs. community B)
| Non-community B | Community B | p-value non- community B. vs. community B | |
|---|---|---|---|
| Number | 13 | 19 | |
| Age [years] | 62.0 (51.0–68.0) | 67.0 (58.0–75.0) | 0.150 |
| ASA status | 2.0 (2.0–2.0) | 3.0 (2.0–3.0) | 0.070 |
| Cardiovascular risk factors | |||
| Coronary heart disease | 1 (7.7%) | 2 (10.5%) | 0.787 |
| Diabetes | 3 (23.1%) | 5 (26.3%) | 0.835 |
| Arterial hypertension | 5 (38.5%) | 8 (42.1%) | 0.837 |
| Chronic renal failure | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Primary disease | |||
| Malignant | 6 (46.2%) | 13 (68.4%) | 0.208 |
| IPMN | 3 (23.1%) | 5 (26.3%) | 0.835 |
| Chronic pancreatitis | 4 (30.8%) | 1 (5.2%) | 0.051 |
| Operation | |||
| Partial pancreaticoduodenectomy | 0 (0.0%) | 7 (36.8%) | 0.013* |
| Pylorus-preserving pancreas head resection | 5 (38.0%) | 6 (31.6%) | 0.687 |
| Total pancreatectomy | 2 (15.4%) | 1 (5.3%) | 0.335 |
| Distal pancreatectomy | 3 (23.1%) | 3 (15.8%) | 0.604 |
| Tumour enucleation | 3 (23.1%) | 2 (10.5%) | 0.337 |
| Surgery [min] | 195.0 (180.0–285.0) | 315.0 (210.0–345.0) | 0.273 |
| Blood loss1 [mL] | 600.0 (200.0–1000.0) | 700 (500–950) | 0.630 |
| Infusion1 [mL] | 3000.0 (2500.0–4000.0) | 3000.0 (2500.0–4000.0) | 0.684 |
| Transfusion1 [mL] | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 1.000 |
| CRP2 [mg/L] | 73.2 (36.1–105.1) | 102.7 (51.6–155.0) | 0.006** |
| Leucocytes2 [1/nL] | 9.0 (7.8–9.9) | 11.1 (8.4–13.8) | 0.022* |
| Hospital stay | |||
| In total [days] | 11.0 (9.0–14.0) | 15.0 (11.0–36.5) | 0.030* |
| Intermediate care unit [days] | 0.0 (0.0–0.0) | 0.0 (0.0–3.0) | 0.439 |
| Intensive care unit [days] | 0.0 (0.0–0.0) | 0.0 (0.0–1.0) | 0.032* |
| Postoperative complications [Clavien-Dindo classification] | |||
| Total number | 3 (23.1%) | 14 (73.7%) | 0.005** |
| Grade I | 2 (15.4%) | 2 (10.5%) | 0.683 |
| Grade II | 1 (7.7%) | 5 (26.3%) | 0.185 |
| Grade III3 | 0 (0.0%) | 6 (31.6%) | 0.044* |
| Grade IV4 | 0 (0.0%) | 2 (10.5%) | 0.227 |
| Grade V | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Outcome | |||
| Survivor 90 days | 13 (100.0%) | 19 (100.0%) | 1.000 |
Data are presented as the median and interquartile range (Q1–Q3) or as count and percentage. A p-value < 0.05 was considered statistically significant and are highlighted in boldface. Concerning symbolism and higher orders of significance: p < 0.05 *, p < 0.01 **, p < 0.001 ***. ASA status, American Society of Anesthesiologists physical status classification system; IPMN, intraductal papillary mucinous neoplasm; CRP, C-reactive protein. 1Two patients suffered from medical and surgical complications, therefore both have been allocated into the medical as well as the surgical complication group; 2total measured intraoperatively; 3postoperative observation period; 4includes grades IIIa and IIIb; 5includes grades IVaand IVb